Stock Details
SNY is Sanofi's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 42.97$. Average daily volumn in 3 months 3.04M. Market cap 94.76B

Stock symbol : SNY. Exchange : NasdaqGS. Currency : USD
Lastest price : 38.02$. Total volume : 2.93M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Sanofi (SNY)
Last Price

Previous Close38.00
Day Range38.01-38.58
Bid38.03 x 1.4k
Ask38.98 x 1.2k
Average Volume3.04M
Market Cap94.76B
52 Week Range36.91-58.10
Trailing P/E14.79
Foward P/E8.62
Dividend (Yield %)4.59%
Ex-Dividend Date2022-05-26

Financial Details

According to Sanofi's financial reports the company's revenue in 2021 were 39.17B an increase( +5.41%) over the years 2020 revenue that were of 37.37B. In 2021 the company's total earnings were 6.22B while total earnings in 2020 were 12.29B(-50%).

Loading ...


Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines ... for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Market Cap:
Total Assets:
Total Cash:

News about "Sanofi"


Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

Source from : Yahoo! Sports - 2 days ago

The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.See details»


Sanofi, Re­gen­eron’s Dupix­ent scores an­oth­er in­di­ca­tion with first-ever ap­proval for nodu­lar skin dis­or­der

Source from : ENDPOINTS NEWS - 2 days ago

Sanofi chief executive Paul Hudson told investors earlier this year that the Big Pharma was going to emphasize its sales kingpin Dupixent moving forward. He wasn't joking — the megablockbuster drug ...See details»


Sanofi us­es cre­ative cam­ou­flage in physi­cian-tar­get­ed cam­paign for po­ten­tial can­cer bio­mark­er

Source from : ENDPOINTS NEWS - 3 days ago

As Sanofi studies a new kind of cancer drug, it’s prepping physicians for its potential biomarker expression. Sanofi’s tusamitamab ravtansine is an antibody-drug conjugate (ADC) that targets ...See details»


French Drugmaker Sanofi Expects Positive Boost From Currency Markets in Q3

Source from : U.S. News & World Report - 4 days ago

PARIS (Reuters) -French drugmaker Sanofi said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by the strength of the U.S. dollar since ...See details»


Sanofi, Scribe Launch Up-to-$1B CRISPR-Based Cancer NK Cell Therapy Collaboration

Source from : GEN - 4 days ago

Sanofi and Scribe Therapeutics will partner to develop CRISPR-based cell therapies to fight cancer, the companies said today. The collaboration could generate more than $1 billion for the CRISPR drug ...See details»


Sanofi partners with Scribe to gain gene editing tools for cell therapy work

Source from : BioPharma Dive - 4 days ago

The California biotech will receive $25 million upfront from Sanofi, which plans to use Scribe’s platform to edit natural killer cells for cancer treatment.See details»


Sanofi turns to startup Scribe to CRISPR edit new NK cell therapies for cancer

Source from : MedCity News - 4 days ago

Sanofi is collaborating with Scribe Therapeutics to use the startup’s CRISPR technology to create cell therapies based on natural killers, a type of immune cell that has cancer-killing capabilities.See details»

Sanofi, Regeneron Say Dupixent Gets FDA Approval to Treat Prurigo Nodularis Skin Disease

Source from : MarketWatch - 3 days ago

By Stephen Nakrosis Sanofi and Regeneron Pharmaceuticals Inc. said Wednesday the Food and Drug Administration approved Dupixent to treat patients ...See details»


Sanofi sees positive impact from currency markets on Q3 results

Source from : Seeking Alpha - 3 days ago

Sanofi (SNY) said it expects a positive impact on its Q3 results due to movements in the currency markets.The French drugmaker said its preliminary estimate of currency impact on ...See details»

PSHAN, SANOFI Sign Agreement to Undertake COVID-19 Vaccine Hesitancy Assessment in Nigeria

Source from : This Day - 2 days ago

The Private Sector Health Alliance of Nigeria (PSHAN) and SANOFI have signed an agreement to undertake a 6 months COVID-19 Vaccine Hesitancy Assessment in Nigeria (C19-VHAN). The study which would ...See details»

Sanofi: Diving Into the Drug Pricing Hit From the Inflation Reduction Act, We’ve Reduced Our FVEs by 2%

Source from : Yahoo Finance - 12 days ago

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the ...See details»


Sanofi (NASDAQ:SNY) Downgraded by TheStreet to “C+”

Source from : Defense World - 13 days ago

TheStreet lowered shares of Sanofi (NASDAQ:SNY – Get Rating) from a b- rating to a c+ rating in a research note released on Thursday, TheStreetRatingsTable reports. Several other analysts also ...See details»

Sanofi (SNY) Moves to Buy: Rationale Behind the Upgrade

Source from : Nasdaq - 11 days ago

Sanofi (SNY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...See details»


Sanofi (NASDAQ:SNY) Shares Acquired by Destiny Wealth Partners LLC

Source from : Defense World - 5 days ago

Destiny Wealth Partners LLC raised its holdings in shares of Sanofi (NASDAQ:SNY – Get Rating) by 162.0% during the second quarter, according to the company in its most recent disclosure with the ...See details»